Alivus Life Sciences Limited
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
What Alivus files
- Investor Meet54
- Others29
- Updates18
- Important9
- Board Meeting8
- PPTs7
Alivus Life Sciences delivered a strong Q1 FY27. Revenue reached ₹640.4 Cr, a 6.4% YoY increase, with PAT soaring 31.8% YoY to ₹160.1 Cr. EPS for the quarter was ₹13.04. This robust performance was largely driven by the non-GPL business, which jumped 26.5% YoY. Margins saw significant improvement, with EBITDA...
Alivus Life Sciences delivered a strong FY26! 💪 Revenue grew 6.9% YoY to ₹ 2,551.8 Cr, with EBITDA up 19.6% to ₹ 857.7 Cr. For Q4FY26, revenue was ₹ 689.1 Cr (+6.1% YoY). The non-GPL business was a key driver, growing 13% YoY and now contributing 71% of total revenue....
Alivus Life Sciences delivered a strong Q3FY26. Revenue from operations grew 4.8% YoY to ₹ 672.9 Cr, with 9MFY26 revenue up 7.2% YoY to ₹ 1,862.7 Cr. Profit after tax (PAT) rose 9.7% YoY to ₹ 150.3 Cr. This performance was largely driven by a significant recovery in the CDMO...
Alivus Life Sciences posted solid Q2FY26 results. Revenue grew 16% YoY to ₹588.0 Cr, fueled by a strong 39.7% YoY surge in the non-GPL business (₹444.3 Cr) across key global markets. The GPL segment (₹143.7 Cr) declined 23.9% YoY due to customer inventory adjustments but anticipates a pickup in H2....
Here's a summary of Alivus Life Sciences' latest investor presentation: **1. Financial Highlights:** Alivus reported Q1 FY26 revenue of ₹601.8 Cr, with EBITDA ₹181.3 Cr (30.1% margin) and PAT ₹121.5 Cr. Gross margin climbed to 55.1%. The company generated a strong ₹100 Cr free cash flow, ending with ₹660.4 Cr...